Malignant melanoma is the most aggressive form of skin cancer and its incidence has increased dramatically in the last two decades. Even with a high rate of success in the treatment of early stages of this malignancy, currently there are no effective strategies for the treatment of advanced metastatic melanoma. Much effort has been put into the use of different target-specific drugs, among which BRAF kinase-specific small-molecule inhibitors have rendered promising results as therapeutic agents in metastatic melanoma. Nonetheless, some side effects, such as development of SCC (squamous cell carcinoma), as well as tumour resistance and recurrence, are common limitations of this therapeutic strategy. The use of combination treatments in which different regulatory pathways or the immunological response are targeted seems to be a promising tool for the future success of melanoma therapeutics.
Review Article| September 26 2011
Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma
Bin Zheng 1
*Institute for Cancer Genetics, Columbia University Medical Center, New York, NY 10032, U.S.A.
†Departments of Dermatology and Pathology & Cell Biology, Columbia University Medical Center, New York, NY 10032, U.S.A.
1To whom correspondence should be addressed (e-mail email@example.com).
Search for other works by this author on:
- Views Icon Views
- Share Icon Share
- Cite Icon Cite
Rolando Pérez-Lorenzo, Bin Zheng; Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Biosci Rep 1 February 2012; 32 (1): 25–33. doi: https://doi.org/10.1042/BSR20110068
Download citation file: